<DOC>
	<DOC>NCT02753647</DOC>
	<brief_summary>This is a prospective, single-arm, open-label phase II study of Chidamide in combination with R-CHOP in the treatment of de novo, elderly, high-risk diffuse large B cell lymphoma patients.</brief_summary>
	<brief_title>Chidamide Plus R-CHOP in Elderly DLBCL</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Pathologically confirmed diffuse large Bcell lymphoma, CD20 positive Age 6175 years ECOG 0,1,2 Life expectancy&gt;6 months Informed consented IPI&gt;1 Chemotherapy before Stem cell transplantation before History of malignancy except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix Uncontrollable cardiocerebral vascular, coagulative, autoimmune, serious infectious disease Primary CNS lymphoma LVEFâ‰¤50% Lab at enrollment (Unless caused by lymphoma) Neutrophile&lt;1.5*10^9/L Platelet&lt;75*10^9/L ALT or AST &gt;2*ULN,AKP or bilirubin &gt;1.5*ULN Creatinine&gt;1.5*ULN Other uncontrollable medical condition that may that may interfere the participation of the study Not able to comply to the protocol for mental or other unknown reasons Pregnant or lactation HIV infection If HbsAg positive, should check HBV DNA, DNA positive patients cannot be enrolled. If HBsAg negative but HBcAb positive (whatever HBsAb status), should check HBV DNA,DNA positive patients cannot be enrolled.</criteria>
	<gender>All</gender>
	<minimum_age>61 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>